Thermo Fisher Scientific

TMO Health Care Market cap $227B as of Sep 14, 2026 16:00 ET S&P 500

Q2 FY26 Mar 29 – Jun 27, 2026 reported Jul 31, 2026

Revenue$11.99B +10% year over year

Gross profit$4.75B 40% margin

Operating profit$2.09B 17% margin

Net profit$1.74B 14% margin

The numbers behind the diagram

All figures in billions of U.S. dollars, for Q2 FY26 (period ends Jun 27, 2026).
Item	Value	Share of revenue	Year over year
Revenue	11.99	100%	+10%
Services	5.17	43%	+12%
Product consumables	5.07	42%
Product instruments	1.75	15%
Cost of revenue	−7.24	60%
Gross profit	4.75	40% margin	+0pp
R&D	−0.36	3%	+0pp
SG&A	−2.30	19%	+0pp
Operating profit	2.09	17% margin	+1pp
Interest & other costs	−0.18
Tax	−0.17
Net profit	1.74	14% margin

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q1 FY26 (period ends Mar 28, 2026).
Item	Value	Share of revenue	Year over year
Revenue	11.01	100%	+6%
Services	4.73	43%	+8%
Consumables	4.72	43%	+8%
Instruments	1.56	14%	−4%
Cost of revenue	−6.66	60%
Gross profit	4.35	40% margin	+0pp
R&D	−0.34	3%	+0pp
SG&A	−2.15	20%	+0pp
Operating profit	1.86	17% margin	+0pp
Interest & other costs	−0.14
Tax	−0.07
Net profit	1.65	15% margin	+0pp

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q4 FY25 (period ends Dec 31, 2025).
Item	Value	Share of revenue	Year over year
Revenue	12.22	100%	+7%
Consumables	5.03	41%	+11%
Services	4.97	41%	+7%
Instruments	2.22	18%	−1%
Cost of revenue	−7.25	59%
Gross profit	4.96	41% margin	+0pp
R&D	−0.36	3%	+0pp
SG&A	−2.35	19%	+0pp
Operating profit	2.26	18% margin	+1pp
Interest & other costs	−0.12
Tax	−0.15
Net profit	1.98	16% margin	+0pp

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q3 FY25 (period ends Sep 27, 2025).
Item	Value	Share of revenue	Year over year
Revenue	11.12	100%	+5%
Consumables	4.68	42%	+7%
Services	4.63	42%	+4%
Instruments	1.81	16%	+2%
Cost of revenue	−6.67	60%
Gross profit	4.45	40% margin	+0pp
R&D	−0.35	3%	+0pp
SG&A	−2.16	20%	+0pp
Operating profit	1.94	17% margin	+0pp
Interest & other costs	−0.12
Tax	−0.21
Net profit	1.62	15% margin	−1pp

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q2 FY25 (period ends Jun 28, 2025).
Item	Value	Share of revenue	Year over year
Revenue	10.86	100%	+3%
Consumables	4.61	43%	+6%
Services	4.61	42%	+5%
Instruments	1.64	15%	−9%
Cost of revenue	−6.53	60%
Gross profit	4.33	40% margin	−1pp
R&D	−0.35	3%	+0pp
SG&A	−2.14	20%	+0pp
Operating profit	1.83	17% margin	+0pp
Interest & other costs	−0.13
Tax	−0.09
Net profit	1.62	15% margin	+0pp

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Filing on EDGAR This quarter on its own page

Financial health

The balance sheet, the quarter's capital flow, the debt schedule and the capital structure of the quarter shown above.

Every set of results we hold, newest first. Open one on its own page.

Quarter	Period	Reported	Revenue	Year over year	Operating margin	Net profit	Net margin
Q2 FY26 Mar 29 – Jun 27, 2026 reported Jul 31, 2026 Operating margin 17% Net profit $1.74B	Mar 29 – Jun 27, 2026	Jul 31, 2026	$12.0B	+10%	17%	$1.74B	14%
Q1 FY26 Jan 1 – Mar 28, 2026 reported May 1, 2026 Operating margin 17% Net profit $1.65B	Jan 1 – Mar 28, 2026	May 1, 2026	$11.0B	+6%	17%	$1.65B	15%
Q4 FY25 Sep 28 – Dec 31, 2025 reported Feb 26, 2026 Operating margin 18% Net profit $1.98B	Sep 28 – Dec 31, 2025	Feb 26, 2026	$12.2B	+7%	18%	$1.98B	16%
Q3 FY25 Jun 29 – Sep 27, 2025 reported Oct 31, 2025 Operating margin 17% Net profit $1.62B	Jun 29 – Sep 27, 2025	Oct 31, 2025	$11.1B	+5%	17%	$1.62B	15%
Q2 FY25 Mar 30 – Jun 28, 2025 reported Aug 1, 2025 Operating margin 17% Net profit $1.62B	Mar 30 – Jun 28, 2025	Aug 1, 2025	$10.9B	+3%	17%	$1.62B	15%